Mural Oncology PLC

Aktienanalyse zu Mural Oncology PLC (MURA)

$2.040

0.000 (0.00%)Zum Schluss

Loading chart…
High
2.040
Open
2.030
VWAP
2.04
Vol
127.78K
Mkt Cap
—
Low
2.030
Amount
260.24K
EV/EBITDA, TTM
0.55

Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.

www.muraloncology.com

Bewertungskennzahlen

The current forward P/E ratio for Mural Oncology PLC (MURA) is -0.78, compared to its 5-year average forward P/E of -0.64.

Forward P/E

Fair
5Y Average P/E
-0.64
Current P/E
-0.78
Überbewertet
-0.33
Unterbewertet
-0.94

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
0.82
Current EV/EBITDA
0.55
Überbewertet
1.48
Unterbewertet
0.15

Forward P/S

Fair
5Y Average P/S
0.08
Current P/S
0.00
Überbewertet
0.64
Unterbewertet
-0.47

Alphio AI Price Scenarios for MURA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MURA

$2.80

Szenariopreis

B

Base

Base · 50%MURA

$2.62

Szenariopreis

B

Bear

Bear · 25%MURA

$2.13

Szenariopreis

Event-Zeitleiste

2025-12-05 (ET)

09:10:00

XOMA Completes Acquisition of Entire Share Capital of Mural Oncology

07:50:00

Mural Oncology Announces Scheme of Arrangement Effective

2025-11-26 (ET)

09:04:43

Mural Oncology Reveals Final Cash Payment Due Upon Acquisition Completion

2025-10-24 (ET)

16:29:41

Mural Oncology Shareholders Give Green Light to XRA 5 Corp. Acquisition

2025-08-20 (ET)

08:35:20

XRA 5 Corp. to Purchase Mural Oncology for $2.035-$2.24 per Share in Cash

Show More Events

News

Show More News

MURA FAQ — answered by Alphio AI

Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten